Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
AB Sciex

Gene Predicts Prognosis of Breast Cancer Patients Treatment Response

By Labmedica International staff writers
Posted on 08 May 2014
Image: The Novolink Detection kit (Photo courtesy of Leica Microsystems).
Image: The Novolink Detection kit (Photo courtesy of Leica Microsystems).
A gene has been identified which, when expressed in breast cancer, can help to predict a patient's chance of recovery and their likely response to chemotherapy.

As recurrence still occurs in over 20% of patients with breast cancer, it is becoming increasingly important to identify biomarkers that can aid in assessing a patient’s risk and response to therapy and which might also act as novel targets for immunotherapies.

Scientists at Nottingham Trent University (Nottingham, UK) studied the biological, prognostic and predictive values of the helicase antigen (HAGE) expression in a total of 2,147 women in three well characterized cohorts of patients with breast cancer. The relationship between HAGE expression and the tumor-infiltrating lymphocytes (TILs) in matched pre-chemotherapy and post-chemotherapy samples was investigated.

The investigators used tissue microarrays (TMAs) and immunohistochemistry (IHC) to study the surgical specimens obtained from the patients. IHC staining was performed using a Novolink Detection kit (Leica Microsystems, Wetzlar, Germany). To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were stained, and the protein expression levels were compared.

The team found that 8% of the women with early primary breast cancer exhibited high HAGE expression (HAGE+) and was associated with aggressive clinicopathological features. Women with breast cancer who were considered to be at low risk, but had a high expression of HAGE, were twice as likely to die, or suffer a relapse, than those with “HAGE negative” tumors. The presence of HAGE also appears to limit the effectiveness of hormone therapy, as high risk patients with HAGE negative breast cancer lived for longer with such therapy.

The study revealed that HAGE can predict a patient's response to chemotherapy, as the incidence of relapse in patients with “HAGE positive” breast cancer following chemotherapy was lower than that in patients whose cancer did not express HAGE. Stephanie McArdle, PhD, a senior research fellow and an author of the study, said, “HAGE is implicated in the progression of breast cancer by driving cell growth, and is associated with higher grade tumors and poorer clinical outcome. This is the first report to show that this molecule is a potential prognostic marker and a predictor of a patient's response to hormone therapy and chemotherapy.” The study was published on April 22, 2014, in the British Journal of Cancer.

Related Links:

Nottingham Trent University
Leica Microsystems 



77 ELEKTRONIKA
DiagCor Bioscience
DRG International
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The API 5000 triple quadruple mass spectrometer (Photo courtesy of AB SCIEX).

Serum Prostate-Specific Antigen Measured by Tandem Mass Spectrometry

Prostate-specific antigen (PSA) is a widely used blood test for detection and monitoring of prostate disease and many clinicians assume that all test methods produce essentially the same results, though... Read more

Industry News

view channel

GlaxoSmithKline Boosts Global Cancer Testing With GE Healthcare Deal

The new agreement between GE Healthcare-subsidiary Clarient (Aliso Viejo, CA, USA) and GlaxoSmithKline (GSK; Brentford, UK) will create a force in cancer testing, according to Kalorama Information (New York City, NY, USA). The two entities will form a multipurpose, data analytics- and companion diagnostics (CDx)-driven... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.